Typically, YAP-driven SOX9 expression is a critical event in the acquisition of CSC properties in esophageal and pancreatic cancer cells, suggesting that YAP inhibition may offer an effective means of therapeutically targeting the CSC population [70, 71]. This evidence concerns the gene YAP1 and familial pancreatic carcinoma.